What Does Heterozygous Paternal HPA Testing Mean for FNAIT?

When reviewing lab results for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk, you might see the word “heterozygous” on your partner’s genetic test (or you might see it written as two different types, like “HPA-1a/1b”). In simple terms, this means your partner carries two different genes for their platelet type: one gene that matches yours (compatible) and one gene that does not (incompatible). This is actually very good news for your future pregnancies. Because he only has one copy of the incompatible gene, there is only a 50/50 chance that he will pass it on to your baby ^[1][2].

The 50/50 Coin Flip

Every person inherits two copies of a gene for human platelet antigens (HPA)—one from their mother and one from their father.

• If a father is homozygous for the incompatible gene, he has two copies of it, meaning he will pass it on 100% of the time, and every future baby will be at risk for FNAIT.
• If a father is heterozygous, he has one incompatible copy and one compatible copy. This makes every pregnancy a coin flip. There is a 50% chance the baby will inherit the incompatible platelet type and be at risk for FNAIT. There is also a 50% chance the baby will inherit the compatible type.

If your baby inherits the compatible type, the baby’s platelets will match yours, meaning your immune system won’t attack them. In this scenario, there is zero risk of FNAIT for that baby, and you will not need any FNAIT-specific treatments or monitoring ^[1][2].

Finding Out Earlier with Specialized NIPT

You don’t have to wait until the baby is born to find out which gene they inherited. Thanks to Non-Invasive Prenatal Testing (NIPT), doctors can determine the baby’s platelet type using a blood draw from the mother ^[3][4].

During pregnancy, small fragments of the baby’s DNA cross the placenta and circulate in the mother’s bloodstream. By analyzing this cell-free fetal DNA (cffDNA), specialists can accurately identify whether the baby has the incompatible HPA gene.

Important details about HPA-NIPT:

• It is a highly specialized test: This is not the standard NIPT used to screen for conditions like Down syndrome. You will likely need to work with a Maternal-Fetal Medicine (MFM) specialist to ensure the correct specialized HPA-NIPT is ordered and sent to the right laboratory.
• Timing and re-draws: The test can theoretically be performed as early as 10 weeks into the pregnancy ^[3][4]. However, sometimes a blood draw this early doesn’t capture enough fetal DNA to give a definitive answer. If this happens, the result may be “inconclusive,” and you may simply need to repeat the blood draw a week or two later.
• Turnaround times: Because this test is sent to specialized labs, results can take a few weeks to come back. If you have previously had a baby with FNAIT, knowing this status early is especially critical so you can begin treatment promptly if needed. Coordinating the timeline with your medical team is crucial.

Tailoring Your Pregnancy Care

Knowing the baby’s genetic status early in the first trimester completely changes how your pregnancy is managed:

• If the HPA-NIPT shows the baby is compatible: You can breathe a sigh of relief. Your pregnancy will be managed like any routine pregnancy, and you can safely avoid intensive FNAIT treatments, such as weekly intravenous immunoglobulin (IVIg) infusions, and invasive diagnostic procedures ^[1][4].
• If the HPA-NIPT shows the baby is incompatible: Your medical team will start you on a carefully monitored treatment plan. This usually involves IVIg therapy, sometimes combined with steroids, which helps protect the baby’s platelets and significantly reduces the risk of severe complications, such as bleeding in the brain (intracranial hemorrhage) ^[5][6].

By combining paternal heterozygous testing with early specialized NIPT, your healthcare team can personalize your care, ensuring you only receive complex therapies when they are actually needed ^[1].